About Us — New Amsterdam Pharma (2024)

NewAmsterdam Pharma

NewAmsterdam Pharma (Nasdaq:NAMS) is a clinical-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated. NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily cholesteryl ester transfer protein (CETP) inhibitor, as the preferred LDL-C lowering therapy to be used as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease patients. Results from NewAmsterdam’s ROSE Phase 2b trial (presented at AHA Scientific Sessions in 2021) included observations that patients receiving obicetrapib 10 mg experienced a median reduction in LDL-C of 51% versus baseline in patients on high-intensity statin therapy (versus a 7% reduction in the placebo arm). Based in the Netherlands, NewAmsterdam was founded in 2019 by the venture capital firm Forbion and John Kastelein, Chief Scientific Officer of NewAmsterdam and closed a $196 million (€160 million) Series A financing in January 2021 led by Forbion, Morningside Ventures, and Ascendant BioCapital. In June 2022, NewAmsterdam entered into an exclusive licensing agreement with the Menarini Group for the commercialization of obicetrapib in Europe, while retaining all rights to commercialize obicetrapib, if approved, in the rest of the world, as well as rights to develop certain forms of obicetrapib for other diseases such as Alzheimer’s disease.

Management Team and Board

We are led and supported by a world-class team of industry veterans and key opinion leaders, including some of the world’s preeminent cardiometabolic experts.

• Management Team
• Non-executive Board
• Executive Board
• Board Observers
• Clinical Advisory Board

Will is the Chair and Chief Executive Officer of Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company focused on serious and rare diseases. He joined Insmed in 2012 as President and CEO and as a member of the board of directors, and became chair of the board in 2018. Will is the former Co-Founder, President, and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), and previously spent more than 10 years working in investment banking in the U.S. and Europe. He also previously worked for the U.S. government.

Will holds a Bachelor of Arts degree cum laude from Oberlin College as well as a Master of Business Administration and a Juris Doctor with Honors from Case Western Reserve University. Will is a member of the Board of Trustees of Case Western Reserve University and a member of the Board of Trustees of BioNJ, the life sciences association for New Jersey.

BOARD OBSERVERS

Wouter Joustra (Forbion)

Wouter Joustra is a General Partner at Forbion and joined the company in 2019 to co-launch Forbion’s Growth Opportunities Fund. Previously, Wouter was a Senior Trader of Life Sciences at Kempen, one of the leading European investment banks focused on Life Sciences and Healthcare. In this role, Wouter ran Kempen’s life sciences portfolio and was involved in deal structuring and equity capital market transactions. Wouter also served as an Executive Board member of Kempen’s life sciences franchise. As part of his portfolio at Forbion, Wouter currently serves as a board member at Gyroscope Therapeutics.

CLINICAL ADVISORY BOARD

Christie Ballantyne

Professor & Chief of Cardiology and Cardiovascular Research, Baylor College of Medicine

Maciej Banach

Head of the Department of Preventive Cardiology and Lipidology, Medical University in Lodz, Poland; Secretary, European Atherosclerosis Society; President, Polish Lipid Association

Alberico Catapano

Full Professor of Pharmacology & Director of the Center of Epidemiology and Preventive Pharmacology, University of Milan; Director of the Laboratory of Lipoproteins, Immunity and Atherosclerosis and the Center for the Study of Atherosclerosis, Bassini Hospital

Brian Ference

Professor and Director of Research, Translational Therapeutics; Executive Director of the Center for Naturally Randomized Trials, University of Cambridge

Ulrich Laufs

Professor of Cardiology, Leipzig University of Germany; Chairman of Cardiology, Leipzig University Hospital

Roxana Mehran

Professor of Medicine & Director of Interventional Cardiovascular Research and Clinical Trials, Cardiovascular Institute at Mount Sinai School of Medicine

Ann Marie Navar

Associate Professor in the Departments of Internal Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center

Stephen Nicholls

Director of the Monash Cardiovascular Research Center, Monash University

Steven E. Nissen

Chairman of the Heart and Vascular Institute, Cleveland Clinic; Professor of Medicine, Lerner College of Medicine

Kosh Ray

Faculty of Medicine at the School of Public Health, Imperial College London